The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Nomura. Did you read the link i sent you. Heres another reason why SGS may have sold
'Further, under the MoU, SGSC has agreed to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street Capital's therapeutic asset AZD1656 of up to £5 million,'
They need the money!!!
SGS may need to pay CIZ a few million..... https://www.lse.co.uk/rns/CIZ/encouraging-progress-on-collaboration-with-sgsc-r3lzcgktqffxu25.html
Also, do you know how much SGS paid for the shares?
Im new here, i took took a position this morning.
VELA RNS shows SGS have sold their shares, maybe SGS need the funds to pay CIZ some royalties.....
https://www.lse.co.uk/rns/VELA/update-re-st-george-street-capital-holding-w9ue8p7a127hru4.html
Nobody knows if it was SGS or not. It could be an individual who needs the cash for a house deposit or something. It could have been me who is intending on stocking up on coke and hookers . We don't know without any cold hard facts.
It’s like asking how long is a piece of string. The fallback on Thursday Friday hasn’t been easy to stomach however remember why you invested here. The director dealings at Igraine… The (now we know) fact that the drug works…. JN invested here (and he is better than me at investing)…. A commercial deal is around the corner…. Backed up with Vela’s other investments…
All the above are facts, not ramping. So that’s why I’m seeing this out for a while yet.
Good post Johnski.
Further to that, the clinical trial clearly states the purpose of the trial is as follows, 'The aim of the study is to determine whether AZD1656 improves clinical outcomes in diabetic patients hospitalised with COVID-19'
Source: https://clinicaltrials.gov/ct2/show/NCT04516759